Taltz (ixekizumab) works by blocking a specific immune protein called interleukin-17A (IL-17A) that drives inflammation in the skin, joints, and spine. It’s a biologic medication, meaning it’s made from living cells and designed to target one precise part of the immune system rather than suppressing immunity broadly. By neutralizing IL-17A, Taltz interrupts the chain of events that causes skin cells to multiply too fast in psoriasis and triggers joint and spinal inflammation in related conditions.
What IL-17A Does in Your Body
IL-17A is a signaling molecule your immune system normally uses to fight infections, particularly bacterial and fungal ones. In autoimmune conditions like psoriasis, your body overproduces IL-17A, which tells skin cells to grow and replace themselves far faster than normal. That rapid turnover creates the thick, red, scaly patches characteristic of plaque psoriasis. The same excess IL-17A also fuels painful inflammation in joints and along the spine.
Taltz is a lab-engineered antibody that latches onto IL-17A molecules circulating in your body and prevents them from attaching to cells. Specifically, it neutralizes both IL-17A homodimers (pairs of identical IL-17A molecules) and IL-17A/F heterodimers (pairs where IL-17A is combined with a related molecule called IL-17F). Once Taltz binds to these molecules, they can no longer trigger the inflammatory cascade. The result is less inflammation, slower skin cell growth, and reduced joint damage over time.
Conditions Taltz Treats
The FDA has approved Taltz for four conditions, all linked to IL-17A overactivity:
- Moderate-to-severe plaque psoriasis in patients 6 years and older who need systemic treatment or phototherapy
- Psoriatic arthritis in adults
- Ankylosing spondylitis, a form of inflammatory arthritis that primarily affects the spine
- Non-radiographic axial spondyloarthritis, a related spinal condition where inflammation is present but hasn’t yet caused visible damage on X-rays
How Quickly Taltz Works
Taltz is one of the faster-acting biologics for psoriasis, partly because of an aggressive loading schedule during the first 12 weeks. For plaque psoriasis, you start with a larger initial dose of 160 mg (given as two injections), then take 80 mg every two weeks through week 12. After that, you shift to a maintenance dose of 80 mg once every four weeks.
For psoriatic arthritis and ankylosing spondylitis, the schedule is simpler: the same 160 mg starting dose, then 80 mg every four weeks from the beginning, with no loading phase of biweekly injections.
In clinical trials, nearly 40% of psoriasis patients on the higher dose achieved completely clear skin (a 100% reduction in their psoriasis severity score) during the initial treatment period, compared to 0% on placebo. About 71% reached 90% clearance. Those numbers continued to improve over time. After a full year of treatment, 95% of a subset of patients maintained at least 90% clearance, and 63% had completely clear skin.
How Taltz Compares to Other Biologics
In a head-to-head trial of 566 patients with psoriatic arthritis, Taltz outperformed adalimumab (Humira), one of the most widely prescribed biologics. At 24 weeks, Taltz was superior in the combined measure of both joint improvement and complete skin clearance. As a standalone measure of skin clearance alone, Taltz was also superior. For joint symptoms specifically, it was shown to be at least as effective as Humira. This trial enrolled patients who had never used a biologic before, so the results reflect first-line performance.
What the Injection Experience Is Like
Taltz is a self-injection you give at home using a prefilled autoinjector pen. The process takes about 10 seconds once the needle is in place. You’ll hear a click when the injection starts and a second click when it’s done. Injection sites include the stomach, thigh, or back of the upper arm.
Before injecting, the pen needs to sit at room temperature for 30 minutes after being removed from the refrigerator. The medication is stored between 36°F and 46°F, protected from light, and should never be frozen or shaken. The liquid should look clear and colorless to slightly yellow. You clean the injection site with an alcohol wipe, twist off the cap, press the base flat against your skin, unlock the ring, and press the button.
Common Side Effects
The most frequent side effect is irritation at the injection site, which affected about 17% of patients in clinical trials compared to 3% on placebo. This typically means redness, mild pain, or swelling where the needle went in, and it usually resolves on its own.
Upper respiratory infections (mostly common colds and similar illnesses) occurred in about 14% of patients, though this was only slightly higher than the 13% rate seen in the placebo group. Nausea affected about 2% of patients. Fungal skin infections, particularly tinea (ringworm-type infections), were more common on Taltz (2%) than placebo (less than 1%). This makes sense given that IL-17A normally helps your body fight fungal infections, so blocking it creates a small vulnerability there.
Less common side effects occurring in under 1% of patients included nasal inflammation, oral yeast infections, hives, flu, and pinkeye. A small drop in a type of white blood cell called neutrophils can also occur, which your doctor will monitor with periodic blood tests.
Important Safety Considerations
Because Taltz partially suppresses immune function, you should not start it during an active infection. Live vaccines should also be avoided while on treatment.
There is a specific concern around inflammatory bowel disease. In clinical trials, new cases or flare-ups of Crohn’s disease (0.1% of patients) and ulcerative colitis (0.2%) occurred at higher rates than with placebo. If you have a history of either condition, this is something to weigh carefully. The connection likely relates to IL-17A’s role in gut immune defense: blocking it can, in rare cases, destabilize the intestinal lining in people who are susceptible.